GGrantIndex
← Leaderboards

Integrated Biotherapeutics, Inc.

Rockville, MD

Compare ↔
$62,413,124
Total funding
29
Grants

Funding over time

peak $10.7M · FY2008–22
$20M$15M$10M$5M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22

Funding mix

By agency

NIH$62,413,124 · 29

By mechanism

N01$22,958,376 · 2
R01$16,563,643 · 4
R43$6,289,352 · 12
U01$5,382,883 · 1
R42$4,509,825 · 2
R44$3,445,591 · 2

Investigators at Integrated Biotherapeutics, Inc.

Investigator-initiatedAll funding

InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).

Rising Stars

First grant in the last 5 yrs

Not enough data

Emerging Leaders

6–10 yrs in

1Shweta Kailasan$1,196,6272 gr2Ramin M. Hakami$1,186,1662 gr3Hatice Karauzum$371,9051 gr

All-Time

Most funded here, all years

1Frederick Wayne Holtsberg$3,471,4495 gr2Rajan P Adhikari$2,976,9405 gr3Shweta Kailasan$1,196,6272 gr4Ramin M. Hakami$1,186,1662 gr5Kelly Lyn Warfield$750,0002 gr6Sven G Enterlein$550,4141 gr7Hatice Karauzum$371,9051 gr

Largest grants

Development of Mutivalent Filovirus (Ebola and Marburg) Vaccines$9,210,189
N01 · FY2010 · AI
Development of Mutivalent Filovirus (Ebola and Marburg) Vaccines$6,180,074
N01 · FY2009 · AI
Development of Mutivalent Filovirus (Ebola and Marburg) Vaccines$5,818,745
N01 · FY2008 · AI
Development of Therapeutic Products for Marburg Virus$1,749,368
N01 · FY2021 · AI
Rationally Designed Pan-Ebolavirus Vaccine$1,691,927
R01 · FY2017 · AI
Rationally Designed Pan-Ebolavirus Vaccine$1,372,407
R01 · FY2018 · AI
Rationally Designed Pan-Ebolavirus Vaccine$1,246,581
R01 · FY2019 · AI
Rationally Designed Pan-Ebolavirus Vaccine$1,240,735
R01 · FY2020 · AI
Therapeutic Human Monoclonal Antibodies Against Staphylococcal Enterotoxin B (SEB$1,217,384
U01 · FY2010 · AI
Therapeutic Human Monoclonal Antibodies Against Staphylococcal Enterotoxin B (SEB$1,214,480
U01 · FY2011 · AI
Therapeutic Human Monoclonal Antibodies Against Staphylococcal Enterotoxin B (SEB$1,200,242
U01 · FY2012 · AI
Therapeutic Human Monoclonal Antibodies Against Staphylococcal Enterotoxin B (SEB$1,031,598
U01 · FY2009 · AI
Immunotherapy of MRSA Osteomyelitis$1,000,000
R44 · FY2022 · AI
Immunotherapy of MRSA Osteomyelitis$1,000,000
R44 · FY2021 · AI
Broadly Protective Bispecific Antibodies for Treatment of Ebola Virus Disease$1,000,000
R42 · FY2018 · AI
Infection Site Targeted Antitoxin Antibody (ISTAb) against Bacillus anthracis$999,997
R42 · FY2019 · AI
Infection Site Targeted Antitoxin Antibody (ISTAb) against Bacillus anthracis$985,298
R42 · FY2020 · AI
Rationally Designed Pan-Ebolavirus Vaccine$886,705
R01 · FY2021 · AI
Broadly Protective Bispecific Antibodies for Treatment of Ebola Virus Disease$861,259
R42 · FY2017 · AI
Development of a Universal Immunotherapeutic for Influenza Viruses$804,193
R44 · FY2021 · AI